上海奥浦迈生物科技股份有限公司第二届董事会第十三次会议决议公告

Group 1 - The company held its 13th meeting of the second board on September 2, 2025, where all 7 directors attended, confirming the legality and validity of the meeting [2][4] - The board approved the adjustment of the fundraising plan for the acquisition, reducing the total amount to 362.05 million yuan, with cash payment and fees adjusted accordingly [2][5] - The board confirmed that the adjustments do not constitute a major change to the transaction plan, as there are no changes to the target assets or transaction parties [5][20] Group 2 - The company’s supervisory board also convened on September 2, 2025, with all 3 supervisors present, and unanimously approved the same adjustments made by the board [13][16] - The independent financial advisor confirmed that the adjustments do not constitute a major change according to relevant regulations [22] - The company plans to acquire 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment [19][24]